JupiteX Get the app
Economy & Business17 Nov 2026 · about 7 min

Why Indian drugmakers are losing pricing power in the US

The brief

Losing pricing power means Indian drugmakers have less ability to keep prices high or negotiate favorable terms in the United States. Buyers are concentrated, and competition among generic suppliers is intense. As prices fall, companies can earn less from each product, squeezing sales and margins even when demand remains. The pressure is visible in recent results. Cipla’s North America revenue fell 19% in rupee terms in the July-September 2026 quarter as generic Revlimid sales declined. Lupin’s US sales fell 13% from the previous quarter after it lost exclusivity on Tolvaptan and Mirabegron. Dr. Reddy’s also reported weaker Revlimid sales. This is a structural challenge, not just a bad quarter. Indian companies supply much of the US generic market, while a few buying groups set terms for purchases. Companies are moving toward complex products that may resist price erosion better, but developing and launching them can take years. Icra expects US growth to improve to 5-7% in 2026-27, aided by launches and acquisitions.

01

What does it mean for Indian drugmakers to lose pricing power in the US?

Losing pricing power means Indian drugmakers have less ability to keep prices high or negotiate favorable terms in the United States. Buyers are concentrated, and competition among generic suppliers is intense. As prices fall, companies can earn less from each product, squeezing sales and margins even when demand remains.

The pressure is visible in recent results. Cipla’s North America revenue fell 19% in rupee terms in the July-September 2026 quarter as generic Revlimid sales declined. Lupin’s US sales fell 13% from the previous quarter after it lost exclusivity on Tolvaptan and Mirabegron. Dr. Reddy’s also reported weaker Revlimid sales.

This is a structural challenge, not just a bad quarter. Indian companies supply much of the US generic market, while a few buying groups set terms for purchases. Companies are moving toward complex products that may resist price erosion better, but developing and launching them can take years. Icra expects US growth to improve to 5-7% in 2026-27, aided by launches and acquisitions.

02

How important is the US market to Indian drugmakers and their exports?

The United States is a major market for Indian drugmakers, both as an export destination and as a source of company revenue. Its importance means that price cuts or lost sales there can affect overall growth and profits. The exposure varies by company, and export figures do not include medicines Indian firms manufacture inside the US.

In 2025-26, US exports of Indian drugs fell nearly 10% to $9.47 billion, while exports to Europe rose 7% and exports to Africa rose 13%. Total drug exports grew 2.1%, meaning exports to destinations outside the US increased 8.5%. The US share of total exports dropped four percentage points to 30%.

Company revenue shows a broader picture of US exposure. The market accounted for 33% of revenue at 25 large listed drugmakers in 2025-26, according to Icra. In the July-September 2026 quarter, it contributed 44% of Aurobindo’s revenue, 42% of Zydus’s and 39% of Lupin’s. Icra projects US growth of 5-7% in 2026-27, supported by new launches and acquisitions.

03

Which falling sales and lost exclusivity deals are putting pressure on Indian drugmakers?

Several products that once supported Indian drugmakers’ US sales are now facing falling prices or new rivals. Generic Revlimid, a blood cancer drug, was a high-margin product until early 2026. At the same time, exclusivity periods on other products have ended, allowing competitors to enter and take sales from companies that previously had a limited field of rivals.

Cipla’s North America revenue fell 19% in rupee terms in the July-September 2026 quarter as generic Revlimid sales declined. Revlimid also weighed on Dr. Reddy’s North America sales. Lupin’s US sales fell 13% from the April-June quarter after it lost exclusivity on Tolvaptan and Mirabegron. Tolvaptan had been a one-maker market for Lupin until two rivals entered in the September quarter.

The pressure also appears in broader company results. Dr. Reddy’s North America generics sales fell 29% in dollar terms to $264 million in the July-September quarter, despite double-digit growth excluding Revlimid. Sun Pharma’s US sales fell 8.2% in the September quarter. Icra expects lower Revlimid sales to contribute to weaker operating margins in 2026-27.

04

How do a few powerful buying groups influence the prices drugmakers can charge?

When a small number of buyers account for most purchases, drugmakers have fewer customers to negotiate with. These powerful groups can influence the terms for generic medicines, where suppliers often compete mainly on price. The result is weaker bargaining power for manufacturers, including Indian companies that supply a large share of US generics.

Three buying groups formed by wholesalers and pharmacy chains between 2012 and 2016 accounted for nearly 80% of US retail generic purchases, according to a 2023 report. Pharmacies also have a reason to seek the lowest prices: they are paid at rates that do not depend on what they paid for a particular generic. A cheaper supplier can therefore raise a pharmacy’s margin.

Wholesale consolidation has reduced Indian suppliers’ bargaining power, Crisil said in 2025. The market is also changing as the two remaining national drugstore chains have closed more than 3,000 stores since 2018. With Indian companies supplying 61% of US generic pills dispensed in 2024, concentrated buyers and price-focused competition leave them particularly exposed.

05

Why do prices for a generic drug usually fall as more manufacturers begin selling it?

A generic drug is usually sold by multiple manufacturers, and each new supplier adds another option for buyers. When buyers can choose among more makers, they can favor lower-priced offers. That competition reduces the price each manufacturer can charge and can make a once-attractive product much less profitable.

The article cites a US health department study of Medicare data from 2007-2022. It found that a generic sells at 75-85% of the brand price when there is one maker, but at 20-30% when there are ten or more. Revlimid illustrates the risk: volume restrictions on existing sellers ended on 31 January 2026, paving the way for new manufacturers.

The pattern makes exclusivity valuable but temporary. Lupin, the only generic maker of kidney drug Tolvaptan, held about half the market until two rivals entered in the July-September quarter. Its CEO said the bigger impact was on pricing. As competition grows, companies need new products to offset price declines, but complex medicines can take years to develop and commercialize.

06

What happens to a drugmaker’s sales and margins when competition increases for a once-profitable drug like Revlimid?

When competition increases for a formerly profitable drug, sellers often have to cut prices to keep or win buyers. That can sharply reduce revenue from the product, especially if it once made up a large share of sales. Lower prices can also weaken overall margins, even if a company’s other products are growing.

Generic Revlimid was a high-margin US product for Indian drugmakers until early 2026. Volume limits under patent settlements ended on 31 January, allowing new manufacturers to sell. Dr. Reddy’s set aside $50 million in the January-March 2026 quarter to compensate buyers for price cuts on stock they held. In the July-September quarter, its North America generics sales fell 29% to $264 million, while sales excluding Revlimid grew by double digits.

The impact extends beyond one company. Based on estimated growth in Dr. Reddy’s base business, Revlimid sales a year earlier were at least $130 million, or more than a third of its total. Icra expects large drugmakers’ operating margins to fall from 24.1% in 2025-26 to 22-23% in 2026-27, partly because Revlimid sales are lower.

07

Why can complex medicines such as biosimilars, inhalers, and injectables hold their prices better than simpler generics?

The article’s central point is that complex products may hold prices better than simpler generics because they are harder to develop and commercialize. It does not specifically name biosimilars, inhalers, or injectables, or explain their individual pricing dynamics. The general idea is that greater technical and manufacturing demands can make it harder for new suppliers to enter quickly.

As general background beyond the article, biosimilars must demonstrate similarity to a reference biologic, while inhalers and injectables can require specialized formulation, device, or manufacturing capabilities. These hurdles may limit the number of competing suppliers compared with a straightforward generic. With fewer rivals, price competition may be less intense, though it is not eliminated.

For Indian drugmakers, this shift is a possible response to US price erosion, not an immediate fix. The article says complex products can take years to develop and commercialize, while simpler products can lose exclusivity and face new rivals quickly. Companies therefore need to balance the longer development path with near-term revenue pressure. The article does not quantify the pricing advantage of these specific product types.

This brief was written by AI from the original reporting and checked by other models. Names, figures and quotes come from the source; read it for full context.

Read more in the JupiteX app

Pulse is free. New stories every 4 hours, each one broken into the questions that explain it.

Or read more news on the web